William P. Schiemann
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
William P. Schiemann has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
Maozhen Tian
Department of Pharmacology, MS-8303, University of Colorado Denver, Anschutz Medical Campus, RC1 South Tower, Rm. L18-6110, 12801 East 17th Ave., PO Box 6511, Aurora, CO 80045, USA
3 shared publications- Michael K. Wendt
Purdue University Institute for Cancer Research, Purdue University, West Lafayette, IN 47907, USA
3 shared publications Amy J. Galliher-Beckley
Department of Pharmacology University of Colorado Denver Anschutz Medical Campus Aurora Colorado USA
1 shared publicationJason A. Smith
1 shared publicationJason R. Neil
Department of Pharmacology, University of Colorado Denver, Anschutz Medical Campus, Aurora, Colorado 80045, USA
1 shared publicationTressa M Allington
Department of Pharmacology, MS-8303, University of Colorado Denver, Anschutz Medical Campus, RC1 South Tower, Room L18–6110, 12801 East 17th Avenue, PO Box 6511, Aurora, CO80045, USA
1 shared publication
Latest Publications
- Open Access
- 1 December 2009
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 284 (49) , 34145-34156
p130Cas Is Required for Mammary Tumor Growth and Transforming Growth Factor-β-mediated Metastasis through Regulation of Smad2/3 Activity
- 1 December 2009
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 284 (49) , 34145-34156
Open Accessp130Cas Is Required for Mammary Tumor Growth and Transforming Growth Factor-β-mediated Metastasis through Regulation of Smad2/3 Activity
- Open Access
- 6 November 2009
- Published by Wiley in The FASEB Journal
- Vol. 24 (4) , 1105-1116
PGE2 receptor EP2 mediates the antagonistic effect of COX‐2 on TGF‐β signaling during mammary tumorigenesis
The molecular mechanisms that enable cyclooxygenase‐2 (COX‐2) and its mediator prostaglandin E2 (PGE2) to inhibit transforming growth factor‐β (TGF‐β) signaling during mammary tumorigenesis remain unknown. We show here that TGF‐β selectively stimulated the expression of the PGE2 receptor EP2, which increased normal and malignant mammary epithelial cell (MEC) invasion, anchorage‐independent growth, and resistance to TGF‐β‐induced cytostasis. Mechanistically, elevated EP2 expression in normal MECs inhibited the coupling of TGF‐β to Smad2/3 activation and plasminogen activator inhibitor‐1 (PAI1) expression, while EP2 deficiency in these same MECs augmented Smad2/3 activation and PAI expression stimulated by TGF‐β. Along these lines, engineering malignant MECs to lack EP2 expression prevented their growth in soft agar, restored their cytostatic response to TGF‐β, decreased their invasiveness in response to TGF‐β, and potentiated their activation of Smad2/3 and expression of PAI stimulated by TGF‐β. More important, we show that COX‐2 or EP2 deficiency both significantly decreased the growth, angiogenesis, and pulmonary metastasis of mammary tumors produced in mice. Collectively, this investigation establishes EP2 as a potent mediator of the anti‐TGF‐β activities elicited by COX‐2/PGE2 in normal and malignant MECs. Our findings also suggest that pharmacological targeting of EP2 receptors may provide new inroads to antagonize the oncogenic activities of TGF‐β during mammary tumorigenesis.—Tian, M., Schiemann, W. P. PGE2 receptor EP2 mediates the antagonistic effect of COX‐2 on TGF‐β signaling during mammary tumorigenesis. FASEB J. 24, 1105–1116 (2010). www.fasebj.org
- 6 November 2009
- Published by Wiley in The FASEB Journal
- Vol. 24 (4) , 1105-1116
Open AccessPGE2 receptor EP2 mediates the antagonistic effect of COX‐2 on TGF‐β signaling during mammary tumorigenesis
The molecular mechanisms that enable cyclooxygenase‐2 (COX‐2) and its mediator prostaglandin E2 (PGE2) to inhibit transforming growth factor‐β (TGF‐β) signaling during mammary tumorigenesis remain unknown. We show here that TGF‐β selectively stimulated the expression of the PGE2 receptor EP2, which increased normal and malignant mammary epithelial cell (MEC) invasion, anchorage‐independent growth, and resistance to TGF‐β‐induced cytostasis. Mechanistically, elevated EP2 expression in normal MECs inhibited the coupling of TGF‐β to Smad2/3 activation and plasminogen activator inhibitor‐1 (PAI1) expression, while EP2 deficiency in these same MECs augmented Smad2/3 activation and PAI expression stimulated by TGF‐β. Along these lines, engineering malignant MECs to lack EP2 expression prevented their growth in soft agar, restored their cytostatic response to TGF‐β, decreased their invasiveness in response to TGF‐β, and potentiated their activation of Smad2/3 and expression of PAI stimulated by TGF‐β. More important, we show that COX‐2 or EP2 deficiency both significantly decreased the growth, angiogenesis, and pulmonary metastasis of mammary tumors produced in mice. Collectively, this investigation establishes EP2 as a potent mediator of the anti‐TGF‐β activities elicited by COX‐2/PGE2 in normal and malignant MECs. Our findings also suggest that pharmacological targeting of EP2 receptors may provide new inroads to antagonize the oncogenic activities of TGF‐β during mammary tumorigenesis.—Tian, M., Schiemann, W. P. PGE2 receptor EP2 mediates the antagonistic effect of COX‐2 on TGF‐β signaling during mammary tumorigenesis. FASEB J. 24, 1105–1116 (2010). www.fasebj.org
- 26 October 2009
- Published by Taylor & Francis in Future Oncology
- Vol. 5 (8) , 1145-1168
Mechanisms of the Epithelial–Mesenchymal Transition by TGF-β
The formation of epithelial cell barriers results from the defined spatiotemporal differentiation of stem cells into a specialized and polarized epithelium, a process termed mesenchymal–epithelial ...
- 26 October 2009
- Published by Taylor & Francis in Future Oncology
- Vol. 5 (8) , 1145-1168
Mechanisms of the Epithelial–Mesenchymal Transition by TGF-β
The formation of epithelial cell barriers results from the defined spatiotemporal differentiation of stem cells into a specialized and polarized epithelium, a process termed mesenchymal–epithelial ...
- 26 October 2009
- Published by Taylor & Francis in Future Oncology
- Vol. 5 (8) , 1109-1111
Epithelial–Mesenchymal Transition in Tumor Metastasis: A Method to the Madness
- 26 October 2009
- Published by Taylor & Francis in Future Oncology
- Vol. 5 (8) , 1109-1111
Epithelial–Mesenchymal Transition in Tumor Metastasis: A Method to the Madness
- Open Access
- 9 September 2009
- Published by Springer Nature in Breast Cancer Research
- Vol. 11 (5) , R68
Therapeutic targeting of the focal adhesion complex prevents oncogenic TGF-β signaling and metastasis
Introduction: Mammary tumorigenesis is associated with the increased expression of several proteins in the focal adhesion complex, including focal adhesion kinase (FAK) and various integrins. Aberrant expression of these molecules occurs concomitant with the conversion of TGF-β function from a tumor suppressor to a tumor promoter. We previously showed that interaction between β3 integrin and TβR-II facilitates TGF-β-mediated oncogenic signaling, epithelial-mesenchymal transition (EMT), and metastasis. However, the molecular mechanisms by which the focal adhesion complex contributes to β3 integrin:TβR-II signaling and the oncogenic conversion of TGF-β remain poorly understood. Methods: FAK expression and activity were inhibited in normal and malignant mammary epithelial cells (MECs) either genetically by using lentiviral-mediated delivery of shRNAs against FAK, or pharmacologically through in vitro and in vivo use of the FAK inhibitors, PF-562271 and PF-573228. Altered Smad2/3 and p38 MAPK activation, migration, EMT, and invasion in response to TGF-β1 were monitored in FAK-manipulated cells. TβR-II expression was increased in metastatic breast cancer cells by retroviral transduction, and the metastasis of FAK- and TβR-II-manipulated tumors was monitored by using bioluminescent imaging. Results: TGF-β stimulation of MECs stabilized and activated FAK in a β3 integrin- and Src-dependent manner. Furthermore, by using the human MCF10A breast cancer progression model, we showed that increased FAK expression in metastatic breast cancer cells mirrored the acquisition of enhanced activation of p38 MAPK by TGF-β. Administering FAK inhibitors or rendering metastatic breast cancer cells FAK deficient abrogated the interaction between β3 integrin and TβR-II, thereby preventing TGF-β from (a) activating p38 MAPK; (b) stimulating MEC invasion, migration, and EMT; and (c) inducing early primary tumor dissemination to the lungs. Finally, in contrast to FAK depletion, adjuvant FAK chemotherapy of mammary tumors decreased their growth in part by diminished macrophage tumor infiltration. Conclusions: Our studies identify an essential function for FAK in mediating the interaction between β3 integrin and TβR-II, and thus in facilitating the oncogenic conversion of TGF-β required for mammary tumor metastasis. Furthermore, this study establishes chemotherapeutic targeting of FAK as an effective, two-pronged approach in preventing tumor progression both by decreasing innate immune cell infiltration, and by inhibiting early TGF-β-dependent metastasis.
- 9 September 2009
- Published by Springer Nature in Breast Cancer Research
- Vol. 11 (5) , R68
Open AccessTherapeutic targeting of the focal adhesion complex prevents oncogenic TGF-β signaling and metastasis
Introduction: Mammary tumorigenesis is associated with the increased expression of several proteins in the focal adhesion complex, including focal adhesion kinase (FAK) and various integrins. Aberrant expression of these molecules occurs concomitant with the conversion of TGF-β function from a tumor suppressor to a tumor promoter. We previously showed that interaction between β3 integrin and TβR-II facilitates TGF-β-mediated oncogenic signaling, epithelial-mesenchymal transition (EMT), and metastasis. However, the molecular mechanisms by which the focal adhesion complex contributes to β3 integrin:TβR-II signaling and the oncogenic conversion of TGF-β remain poorly understood. Methods: FAK expression and activity were inhibited in normal and malignant mammary epithelial cells (MECs) either genetically by using lentiviral-mediated delivery of shRNAs against FAK, or pharmacologically through in vitro and in vivo use of the FAK inhibitors, PF-562271 and PF-573228. Altered Smad2/3 and p38 MAPK activation, migration, EMT, and invasion in response to TGF-β1 were monitored in FAK-manipulated cells. TβR-II expression was increased in metastatic breast cancer cells by retroviral transduction, and the metastasis of FAK- and TβR-II-manipulated tumors was monitored by using bioluminescent imaging. Results: TGF-β stimulation of MECs stabilized and activated FAK in a β3 integrin- and Src-dependent manner. Furthermore, by using the human MCF10A breast cancer progression model, we showed that increased FAK expression in metastatic breast cancer cells mirrored the acquisition of enhanced activation of p38 MAPK by TGF-β. Administering FAK inhibitors or rendering metastatic breast cancer cells FAK deficient abrogated the interaction between β3 integrin and TβR-II, thereby preventing TGF-β from (a) activating p38 MAPK; (b) stimulating MEC invasion, migration, and EMT; and (c) inducing early primary tumor dissemination to the lungs. Finally, in contrast to FAK depletion, adjuvant FAK chemotherapy of mammary tumors decreased their growth in part by diminished macrophage tumor infiltration. Conclusions: Our studies identify an essential function for FAK in mediating the interaction between β3 integrin and TβR-II, and thus in facilitating the oncogenic conversion of TGF-β required for mammary tumor metastasis. Furthermore, this study establishes chemotherapeutic targeting of FAK as an effective, two-pronged approach in preventing tumor progression both by decreasing innate immune cell infiltration, and by inhibiting early TGF-β-dependent metastasis.
- Open Access
- 18 August 2009
- Published by Wiley in The FASEB Journal
- Vol. 23 (12) , 4231-4243
Activated Abl kinase inhibits oncogenic transforming growth factor‐β signaling and tumorigenesis in mammary tumors
Transforming growth factor‐β (TGF‐β) is a ubiquitous cytokine with dual roles in tumor suppression and promotion, and these dichotomous functions have frustrated the development of therapies targeting oncogenic signaling by TGF‐β. In comparison, Abl is well established as an initiator of hematopoietic cancers; however, a clear role for Abl in regulating solid tumor development remains elusive. Here, we investigated the role of Abl in TGF‐β‐mediated epithelial‐mesenchymal transition (EMT) in normal and meta‐static mammary epithelial cells (MECs). In doing so, we identified Abl as an essential regulator of MEC morphology and showed that Abl inactivation was sufficient to induce phenotypic and transcriptional EMT in normal MECs. Increasing Abl activity in metastatic MECs resulted in their complete morphological reversion, restored their cytostatic response to TGF‐β, and blocked their secretion of matrix metalloproteinases induced by TGF‐β. Constitutively active Abl expression blocked TGF‐ß‐responsive mammary tumor growth in mice, while Imatinib therapy afforded no clinical benefit in mice bearing mammary tumors. Collectively, this investigation establishes Abl as a potent mediator of MEC identity, and as a suppressor of oncogenic TGF‐β signaling during mammary tumorigenesis. Notably, our findings strongly caution against the use of pharmacological Abl antagonists in the treatment of developing and progressing mammary tumors.— Allington, T. M., Galliher‐Beckley, A. J., Schiemann, W. P. Activated Abl kinase inhibits oncogenic transforming growth factor‐β signaling and tumorigenesis in mammary tumors. FASEBJ. 23, 4231‐4243 (2009). www.fasebj.org
- 18 August 2009
- Published by Wiley in The FASEB Journal
- Vol. 23 (12) , 4231-4243
Open AccessActivated Abl kinase inhibits oncogenic transforming growth factor‐β signaling and tumorigenesis in mammary tumors
Transforming growth factor‐β (TGF‐β) is a ubiquitous cytokine with dual roles in tumor suppression and promotion, and these dichotomous functions have frustrated the development of therapies targeting oncogenic signaling by TGF‐β. In comparison, Abl is well established as an initiator of hematopoietic cancers; however, a clear role for Abl in regulating solid tumor development remains elusive. Here, we investigated the role of Abl in TGF‐β‐mediated epithelial‐mesenchymal transition (EMT) in normal and meta‐static mammary epithelial cells (MECs). In doing so, we identified Abl as an essential regulator of MEC morphology and showed that Abl inactivation was sufficient to induce phenotypic and transcriptional EMT in normal MECs. Increasing Abl activity in metastatic MECs resulted in their complete morphological reversion, restored their cytostatic response to TGF‐β, and blocked their secretion of matrix metalloproteinases induced by TGF‐β. Constitutively active Abl expression blocked TGF‐ß‐responsive mammary tumor growth in mice, while Imatinib therapy afforded no clinical benefit in mice bearing mammary tumors. Collectively, this investigation establishes Abl as a potent mediator of MEC identity, and as a suppressor of oncogenic TGF‐β signaling during mammary tumorigenesis. Notably, our findings strongly caution against the use of pharmacological Abl antagonists in the treatment of developing and progressing mammary tumors.— Allington, T. M., Galliher‐Beckley, A. J., Schiemann, W. P. Activated Abl kinase inhibits oncogenic transforming growth factor‐β signaling and tumorigenesis in mammary tumors. FASEBJ. 23, 4231‐4243 (2009). www.fasebj.org
- Open Access
- 1 August 2009
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 284 (32) , 21209-21217
X-linked Inhibitor of Apoptosis Protein and Its E3 Ligase Activity Promote Transforming Growth Factor-Β-mediated Nuclear Factor-κB Activation during Breast Cancer Progression
- 1 August 2009
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 284 (32) , 21209-21217
Open AccessX-linked Inhibitor of Apoptosis Protein and Its E3 Ligase Activity Promote Transforming Growth Factor-Β-mediated Nuclear Factor-κB Activation during Breast Cancer Progression
- 16 March 2009
- Published by Taylor & Francis in Future Oncology
- Vol. 5 (2) , 259-271
The TGF-β Paradox in Human Cancer: An Update
TGF-β plays an essential role in maintaining tissue homeostasis through its ability to induce cell cycle arrest, differentiation and apoptosis, and to preserve genomic stability. Thus, TGF-β is a potent anticancer agent that prohibits the uncontrolled proliferation of epithelial, endothelial and hematopoietic cells. Interestingly, tumorigenesis typically elicits aberrations in the TGF-β signaling pathway that engenders resistance to the cytostatic activities of TGF-β, thereby enhancing the development and progression of human malignancies. Moreover, these genetic and epigenetic events conspire to convert TGF-β from a suppressor of tumor formation to a promoter of their growth, invasion and metastasis. The dichotomous nature of TGF-β during tumorigenesis is known as the ‘TGF-β paradox’, which remains the most critical and mysterious question concerning the physiopathological role of this multifunctional cytokine. Here we review recent findings that directly impact our understanding of the TGF-β paradox and...
- 16 March 2009
- Published by Taylor & Francis in Future Oncology
- Vol. 5 (2) , 259-271
The TGF-β Paradox in Human Cancer: An Update
TGF-β plays an essential role in maintaining tissue homeostasis through its ability to induce cell cycle arrest, differentiation and apoptosis, and to preserve genomic stability. Thus, TGF-β is a potent anticancer agent that prohibits the uncontrolled proliferation of epithelial, endothelial and hematopoietic cells. Interestingly, tumorigenesis typically elicits aberrations in the TGF-β signaling pathway that engenders resistance to the cytostatic activities of TGF-β, thereby enhancing the development and progression of human malignancies. Moreover, these genetic and epigenetic events conspire to convert TGF-β from a suppressor of tumor formation to a promoter of their growth, invasion and metastasis. The dichotomous nature of TGF-β during tumorigenesis is known as the ‘TGF-β paradox’, which remains the most critical and mysterious question concerning the physiopathological role of this multifunctional cytokine. Here we review recent findings that directly impact our understanding of the TGF-β paradox and...